Notably, the present study first identified HME as a potent blocker for STAT3 signaling in bladder cancer cells, as HME markedly inhibited both constitutive and IL-6-inducible STAT3 activation (Figure 3A,B). The gene discussed is STAT3; the disease is urinary bladder cancer.